TABLE 2.
Treatment‐related TEAEs in ≥10% of all patients
| Treatment‐related TEAEs, n (%) | Overall population (N = 43); severity of event | ||
|---|---|---|---|
| Any grade a | Grade 3 | Grade 4 | |
| Hematologic events | |||
| Leukopenia | 24 (55.8) | 12 (27.9) | 3 (7.0) |
| Neutropenia | 24 (55.8) | 7 (16.3) | 16 (37.2) |
| Thrombocytopenia | 23 (53.5) | 0 | 0 |
| Anemia | 7 (16.3) | 2 (4.7) | 0 |
| Febrile neutropenia | 5 (11.6) | 5 (11.6) | 0 |
| Nonhematologic events | |||
| Aspartate aminotransferase increased | 22 (51.2) | 2 (4.7) | 0 |
| Decreased appetite | 20 (46.5) | 1 (2.3) | 0 |
| Stomatitis | 19 (44.2) | 0 | 0 |
| Alanine aminotransferase increased | 16 (37.2) | 3 (7.0) | 0 |
| Alopecia | 16 (37.2) | 0 | 0 |
| Nausea | 14 (32.6) | 1 (2.3) | 0 |
| Peripheral sensory neuropathy | 13 (30.2) | 0 | 0 |
| Fatigue | 12 (27.9) | 0 | 0 |
| Pyrexia | 11 (25.6) | 0 | 0 |
| Gamma‐glutamyl transferase increased | 10 (23.3) | 2 (4.7) | 0 |
| Rash, maculopapular | 9 (20.9) | 1 (2.3) | 0 |
| Blood alkaline phosphatase increased | 7 (16.3) | 0 | 0 |
| Drug hypersensitivity | 6 (14.0) | 1 (2.3) | 0 |
| Dysgeusia | 6 (14.0) | 0 | 0 |
| Malaise | 6 (14.0) | 0 | 0 |
| Rash | 6 (14.0) | 0 | 0 |
| Constipation | 5 (11.6) | 0 | 0 |
TEAE, treatment‐emergent adverse event.
a
No Grade 5 treatment‐related TEAEs occurred.